Sabine Bahn

List of Publications by Year
in descending order

88 papers	3,523 citations	186265 28 h-index	155660 55 g-index
97 all docs	97 docs citations	97 times ranked	5756 citing authors

#	Article	IF	Citations
1	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16136-16141.	7.1	545
2	Transcriptional neoteny in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5743-5748.	7.1	347
3	Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophrenia Research, 2014, 154, 23-29.	2.0	171
4	Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial. Biomarker Insights, 2015, 10, BMI.S22007.	2.5	109
5	Neuroimmune biomarkers in schizophrenia. Schizophrenia Research, 2016, 176, 3-13.	2.0	109
6	Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Medical Genomics, 2009, 2, 28.	1.5	97
7	Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology, 2013, 38, 752-766.	2.7	93
8	Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. International Journal of Neuropsychopharmacology, 2014, 17, 1599-1608.	2.1	91
9	Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways. Schizophrenia Bulletin, 2014, 40, 787-795.	4.3	84
10	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1.. International Journal of Neuropsychopharmacology, 2015, 18, pyv042.	2.1	84
11	Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Progress in Neurobiology, 2014, 122, 45-72.	5.7	77
12	Spatial and temporal diversity of glycome expression in mammalian brain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28743-28753.	7.1	67
13	Alteration of Neuronal Excitability and Short-Term Synaptic Plasticity in the Prefrontal Cortex of a Mouse Model of Mental Illness. Journal of Neuroscience, 2017, 37, 4158-4180.	3.6	64
14	Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins. Molecular Autism, 2014, 5, 41.	4.9	63
15	Towards a blood-based diagnostic panel for bipolar disorder. Brain, Behavior, and Immunity, 2016, 52, 49-57.	4.1	59
16	Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome. Molecular Autism, 2014, 5, 4.	4.9	57
17	Sex Differences in Serum Markers of Major Depressive Disorder in the Netherlands Study of Depression and Anxiety (NESDA). PLoS ONE, 2016, 11, e0156624.	2.5	54
18	Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis. Psychoneuroendocrinology, 2018, 90, 35-42.	2.7	47

#	Article	IF	Citations
19	Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment. Schizophrenia Bulletin, 2020, 46, 363-373.	4.3	46
20	Oxidative stress in drug-naÃ¯ve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 129-143.	3.2	45
21	Proteomic Enrichment Analysis of Psychotic and Affective Disorders Reveals Common Signatures in Presynaptic Glutamatergic Signaling and Energy Metabolism. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	44
22	Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. JAMA Psychiatry, 2019, 76, 864.	11.0	43
23	A machine learning algorithm to differentiate bipolar disorder from major depressive disorder using an online mental health questionnaire and blood biomarker data. Translational Psychiatry, 2021, 11, 41.	4.8	41
24	Targeted Multiplexed Selected Reaction Monitoring Analysis Evaluates Protein Expression Changes of Molecular Risk Factors for Major Psychiatric Disorders. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	36
25	Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. Molecular Autism, 2014, 5, 38.	4.9	33
26	Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. Journal of Psychiatric Research, 2015, 60, 40-48.	3.1	31
27	Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3Î² signaling in bipolar patients. Journal of Affective Disorders, 2014, 156, 139-143.	4.1	30
28	Variation in serum biomarkers with sex and female hormonal status: implications for clinical tests. Scientific Reports, 2016, 6, 26947.	3.3	30
29	Towards reproducible MRM based biomarker discovery using dried blood spots. Scientific Reports, 2017, 7, 45178.	3.3	30
30	Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots. Translational Psychiatry, 2017, 7, 1290.	4.8	30
31	Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders. Expert Review of Proteomics, 2018, 15, 325-340.	3.0	30
32	The association between antibodies to neurotropic pathogens and schizophrenia: a case-control study. NPJ Schizophrenia, 2015, 1, 15041.	3.6	29
33	Association of DNA Methylation with Acute Mania and Inflammatory Markers. PLoS ONE, 2015, 10, e0132001.	2.5	28
34	Proteomics: improving biomarker translation to modern medicine?. Genome Medicine, 2013, 5, 17.	8.2	27
35	Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain, Behavior, and Immunity, 2016, 52, 178-186.	4.1	26
36	Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis. European Neuropsychopharmacology, 2019, 29, 835-846.	0.7	26

#	ARTICLE	IF	CITATIONS
37	Blood-based immune-endocrine biomarkers of treatment response inÂdepression. Journal of Psychiatric Research, 2016, 83, 249-259.	3.1	24
38	Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial. Schizophrenia Bulletin, 2021, 47, 1108-1115.	4.3	24
39	Temporal proteomic profiling of postnatal human cortical development. Translational Psychiatry, 2018, 8, 267.	4.8	22
40	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. Science Advances, 2019, 5, eaau9093.	10.3	22
41	Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks. Molecular Psychiatry, 2020, 25, 2355-2372.	7.9	22
42	Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics - Clinical Applications, 2015, 9, 907-916.	1.6	21
43	Synaptic vesicle dynamic changes in a model of fragile X. Molecular Autism, 2016, 7, 17.	4.9	21
44	Associations between SNPs and immune-related circulating proteins in schizophrenia. Scientific Reports, 2017, 7, 12586.	3.3	21
45	Molecular serum signature of treatment resistant depression. Psychopharmacology, 2016, 233, 3051-3059.	3.1	20
46	Lithium reverses behavioral and axonal transport-related changes associated with ANK3 bipolar disorder gene disruption. European Neuropsychopharmacology, 2017, 27, 274-288.	0.7	20
47	Converging evidence points towards a role of insulin signaling in regulating compulsive behavior. Translational Psychiatry, 2019, 9, 225.	4.8	20
48	Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Medicine, 2013, 5, 25.	8.2	19
49	Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles. Trends in Biotechnology, 2015, 33, 712-723.	9.3	19
50	A brain proteomic investigation of rapamycin effects in the Tsc1 +/â~ mouse model. Molecular Autism, 2017, 8, 41.	4.9	19
51	Denser brain capillary network with preserved pericytes in Alzheimer's disease. Brain Pathology, 2020, 30, 1071-1086.	4.1	19
52	Challenges of Introducing New Biomarker Products for Neuropsychiatric Disorders into the Market. International Review of Neurobiology, 2011, 101, 299-327.	2.0	18
53	Shared Immune and Repair Markers During Experimental <i>Toxoplasma</i> Chronic Brain Infection and Schizophrenia. Schizophrenia Bulletin, 2016, 42, 386-395.	4.3	18
54	A Combined Digital and Biomarker Diagnostic Aid for Mood Disorders (the Delta Trial): Protocol for an Observational Study. JMIR Research Protocols, 2020, 9, e18453.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients. Brain, Behavior, and Immunity, 2018, 67, 364-373.	4.1	17
56	Multimodel inference for biomarker development: an application to schizophrenia. Translational Psychiatry, 2019, 9, 83.	4.8	17
57	Identification of altered dipeptidyl-peptidase activities as potential biomarkers for unipolar depression. Journal of Affective Disorders, 2013, 151, 667-672.	4.1	16
58	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. Brain, Behavior, and Immunity, 2021, 91, 673-682.	4.1	15
59	Hippocampal Proteomic and Metabonomic Abnormalities in Neurotransmission, Oxidative Stress, and Apoptotic Pathways in a Chronic Phencyclidine Rat Model. Journal of Proteome Research, 2015, 14, 3174-3187.	3.7	14
60	Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients. Journal of Affective Disorders, 2015, 185, 12-16.	4.1	14
61	Building the Digital Mental Health Ecosystem: Opportunities and Challenges for Mobile Health Innovators. Journal of Medical Internet Research, 2021, 23, e27507.	4.3	14
62	mHealth Solutions for Mental Health Screening and Diagnosis: A Review of App User Perspectives Using Sentiment and Thematic Analysis. Frontiers in Psychiatry, 2022, 13, 857304.	2.6	14
63	The need for a comprehensive molecular characterization of autism spectrum disorders. International Journal of Neuropsychopharmacology, 2014, 17, 651-673.	2.1	13
64	Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology. Schizophrenia Research, 2016, 177, 98-107.	2.0	13
65	Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. ACS Chemical Neuroscience, 2019, 10, 58-78.	3.5	13
66	mHealth Solutions for Perinatal Mental Health: Scoping Review and Appraisal Following the mHealth Index and Navigation Database Framework. JMIR MHealth and UHealth, 2022, 10, e30724.	3.7	13
67	Diagnostic prediction model development using data from dried blood spot proteomics and a digital mental health assessment to identify major depressive disorder among individuals presenting with low mood. Brain, Behavior, and Immunity, 2020, 90, 184-195.	4.1	12
68	Proof-of-Concept Support for the Development and Implementation of a Digital Assessment for Perinatal Mental Health: Mixed Methods Study. Journal of Medical Internet Research, 2021, 23, e27132.	4.3	12
69	The Current State and Validity of Digital Assessment Tools for Psychiatry: Systematic Review. JMIR Mental Health, 2022, 9, e32824.	3.3	12
70	Novel open reading frames in human accelerated regions and transposable elements reveal new leads to understand schizophrenia and bipolar disorder. Molecular Psychiatry, 2022, 27, 1455-1468.	7.9	11
71	Technological advances for deciphering the complexity of psychiatric disorders: merging proteomics with cell biology. International Journal of Neuropsychopharmacology, 2014, 17, 1327-1341.	2.1	10
72	Integrating proteomic, sociodemographic and clinical data to predict future depression diagnosis in subthreshold symptomatic individuals. Translational Psychiatry, 2019, 9, 277.	4.8	10

#	Article	IF	Citations
73	The Current State and Diagnostic Accuracy of Digital Mental Health Assessment Tools for Psychiatric Disorders: Protocol for a Systematic Review and Meta-analysis. JMIR Research Protocols, 2021, 10, e25382.	1.0	10
74	What Can We Learn About Depression from Gene Expression in Peripheral Tissues?. Biological Psychiatry, 2015, 77, 207-209.	1.3	9
75	Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression. Frontiers in Psychiatry, 2020, 11, 189.	2.6	9
76	Cell Type-Specific Effects of Mutant DISC1: A Proteomics Study. Molecular Neuropsychiatry, 2016, 2, 28-36.	2.9	8
77	Evaluation of molecular brain changes associated with environmental stress in rodent models compared to human major depressive disorder: A proteomic systems approach. World Journal of Biological Psychiatry, 2018, 19, S63-S74.	2.6	8
78	The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. Npj Genomic Medicine, 2022, 7, 25.	3.8	8
79	Functional patient-derived cellular models for neuropsychiatric drug discovery. Translational Psychiatry, 2021, 11, 128.	4.8	7
80	Virus discovery analyses on post-mortem brain tissue and cerebrospinal fluid of schizophrenia patients. Schizophrenia Research, 2018, 197, 605-606.	2.0	6
81	Impact of a Web-Based Psychiatric Assessment on the Mental Health and Well-Being of Individuals Presenting With Depressive Symptoms: Longitudinal Observational Study. JMIR Mental Health, 2021, 8, e23813.	3.3	6
82	Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment. PLoS ONE, 2018, 13, e0192278.	2.5	5
83	The Delta Study â€" Prevalence and characteristics of mood disorders in 924 individuals with low mood: Results of the of the World Health Organization Composite International Diagnostic Interview (CIDI). Brain and Behavior, 2021, 11, e02167.	2.2	4
84	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naÃ¯ve schizophrenia. Brain, Behavior, and Immunity, 2022, 103, 37-49.	4.1	4
85	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
86	Toward an Extended Definition of Major Depressive Disorder Symptomatology: Digital Assessment and Cross-validation Study. JMIR Formative Research, 2021, 5, e27908.	1.4	1
87	Personality, symptom, and demographic correlates of perceived efficacy of selective serotonin reuptake inhibitor monotherapy among current users with low mood: A data-driven approach. Journal of Affective Disorders, 2021, 295, 1122-1130.	4.1	1
88	Using decision-analysis modelling to estimate the economic impact of the identification of unrecognised bipolar disorder in primary care: the untapped potential of screening. International Journal of Bipolar Disorders, 2022, 10, .	2.2	1